Equities research analysts expect Idexx Laboratories (NASDAQ:IDXX) to announce earnings of $1.18 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Idexx Laboratories’ earnings, with estimates ranging from $1.16 to $1.21. Idexx Laboratories posted earnings per share of $0.95 in the same quarter last year, which suggests a positive year over year growth rate of 24.2%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 7th.
On average, analysts expect that Idexx Laboratories will report full year earnings of $4.16 per share for the current year, with EPS estimates ranging from $4.09 to $4.21. For the next year, analysts anticipate that the company will post earnings of $4.90 per share, with EPS estimates ranging from $4.80 to $5.03. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Idexx Laboratories.
Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Friday, May 4th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.09. Idexx Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. The business had revenue of $537.60 million during the quarter, compared to the consensus estimate of $525.14 million. During the same period in the prior year, the company posted $0.77 EPS. The firm’s revenue for the quarter was up 16.4% compared to the same quarter last year.
IDXX has been the topic of several recent research reports. Stifel Nicolaus upped their price objective on Idexx Laboratories from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, May 7th. Zacks Investment Research raised Idexx Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price objective on the stock in a report on Monday, February 5th. BidaskClub cut Idexx Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 9th. Canaccord Genuity reaffirmed a “positive” rating and set a $215.00 price objective on shares of Idexx Laboratories in a report on Monday, May 7th. Finally, ValuEngine raised Idexx Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Idexx Laboratories presently has a consensus rating of “Buy” and an average target price of $201.43.
In related news, Director Daniel M. Junius sold 2,974 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $190.06, for a total transaction of $565,238.44. Following the sale, the director now owns 5,602 shares in the company, valued at approximately $1,064,716.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William T. End sold 9,470 shares of the stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $208.36, for a total value of $1,973,169.20. Following the sale, the director now owns 31,786 shares in the company, valued at approximately $6,622,930.96. The disclosure for this sale can be found here. Insiders have sold a total of 16,444 shares of company stock worth $3,276,328 over the last ninety days. Insiders own 2.56% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. CIBC World Markets Inc. purchased a new stake in Idexx Laboratories during the 1st quarter valued at $5,209,000. Moors & Cabot Inc. purchased a new stake in Idexx Laboratories during the 1st quarter valued at $470,000. Xact Kapitalforvaltning AB raised its holdings in Idexx Laboratories by 5.8% during the 1st quarter. Xact Kapitalforvaltning AB now owns 14,443 shares of the company’s stock valued at $2,764,000 after buying an additional 787 shares during the period. Select Equity Group L.P. raised its holdings in Idexx Laboratories by 21.3% during the 1st quarter. Select Equity Group L.P. now owns 429,006 shares of the company’s stock valued at $82,107,000 after buying an additional 75,410 shares during the period. Finally, Coldstream Capital Management Inc. purchased a new stake in Idexx Laboratories during the 1st quarter valued at $251,000. Institutional investors own 87.72% of the company’s stock.
Shares of IDXX traded up $5.17 during mid-day trading on Friday, hitting $200.76. 523,200 shares of the stock were exchanged, compared to its average volume of 539,929. The stock has a market capitalization of $17.32 billion, a price-to-earnings ratio of 61.21, a price-to-earnings-growth ratio of 2.37 and a beta of 0.60. Idexx Laboratories has a 52-week low of $146.09 and a 52-week high of $217.89. The company has a debt-to-equity ratio of -12.43, a current ratio of 0.96 and a quick ratio of 0.72.
About Idexx Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Get a free copy of the Zacks research report on Idexx Laboratories (IDXX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Idexx Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.